Ohsu Knight Cancer Institute
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 38
- Registration Number
- NCT06320405
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
Phase 1
Recruiting
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration and BiopsyProcedure: Computed TomographyDrug: CyclophosphamideDrug: DoxorubicinProcedure: EchocardiographyDrug: EtoposideProcedure: Magnetic Resonance ImagingBiological: MosunetuzumabProcedure: Multigated Acquisition ScanProcedure: Positron Emission TomographyDrug: PrednisoneDrug: Vincristine
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT06249191
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 150
- Registration Number
- NCT06157099
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Use of Indocyanine Green in Pancreas Surgery
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 55
- Registration Number
- NCT06084013
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
An Exercise Prehabilitation Intervention for Improving Mobility and Recovery Outcomes in Patients Undergoing Head and Neck Cancer Surgery
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT06079697
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 90
- Registration Number
- NCT06067438
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
EMBRACE: Exercising Together
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 400
- Registration Number
- NCT06049355
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Internet-Based Lifestyle Intervention (iLIVE) to Eradicate Obese Frailty in Prostate Cancer Survivors
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 250
- Registration Number
- NCT06011499
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT05943496
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT05937776
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
© Copyright 2024. All Rights Reserved by MedPath